T cell engagers: expanding horizons in oncology and beyond.
Albayrak G. et al, (2025), Br J Cancer, 133, 1241 - 1249
Deregulation of HLA-I in cancer and its central importance for immunotherapy.
Hazini A. et al, (2021), J Immunother Cancer, 9
Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus.
Hill C. et al, (2021), Mol Ther Oncolytics, 21, 47 - 61
Tackling HLA Deficiencies Head on with Oncolytic Viruses.
Fisher K. et al, (2021), Cancers (Basel), 13
The role of cancer metabolism in defining the success of oncolytic viro-immunotherapy.
Dyer A. et al, (2020), Cytokine Growth Factor Rev, 56, 115 - 123
NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer.
Leung EYL. et al, (2020), Mol Ther Oncolytics, 16, 289 - 301
External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase.
Pokrovska TD. et al, (2020), Cancers (Basel), 12
Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.
Scott EM. et al, (2019), J Immunother Cancer, 7
Polyvalent Diazonium Polymers Provide Efficient Protection of Oncolytic Adenovirus Enadenotucirev from Neutralizing Antibodies while Maintaining Biological Activity In Vitro and In Vivo.
Francini N. et al, (2019), Bioconjug Chem, 30, 1244 - 1257
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE).
Machiels J-P. et al, (2019), J Immunother Cancer, 7
An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells.
Freedman JD. et al, (2018), Cancer Res, 78, 6852 - 6865
Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells.
Lei J. et al, (2018), J Immunother Cancer, 6
Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.
Scott EM. et al, (2018), Macromol Biosci, 18
Optimizing the tolerability of intravenous oncolytic viral immunotherapy administration: A sub-analysis of tolerability and cytokine data from the EVOLVE study of enadenotucirev (EnAd), an oncolytic adenovirus
McElwaine-Johnn H. et al, (2017), Annals of Oncology, 28
Making Oncolytic Virotherapy a Clinical Reality: The European Contribution.
Duffy MR. et al, (2017), Hum Gene Ther, 28, 1033 - 1046
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.
Garcia-Carbonero R. et al, (2017), J Immunother Cancer, 5
Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.
Freedman JD. et al, (2017), EMBO Mol Med, 9, 1067 - 1087
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus.
Illingworth S. et al, (2017), Mol Ther Oncolytics, 5, 62 - 74